A Janus kinase inhibitor, also known as JAK inhibitor or jakinib,[1] is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway in lymphocytes.
It is used in the treatment of cancer and inflammatory diseases[1][2] such as rheumatoid arthritis[3] and various skin conditions.[4] A Janus kinase 3 inhibitor is attractive as a possible treatment of various autoimmune diseases since its function is mainly restricted to lymphocytes. As of 2017, development of a selective JAK3 inhibitor was ongoing.[5]
^ abKontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ (August 2012). "Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease". Current Opinion in Pharmacology. 12 (4): 464–70. doi:10.1016/j.coph.2012.06.008. PMC 3419278. PMID 22819198.
^Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ (June 2008). "Therapeutic targeting of Janus kinases". Immunological Reviews. 223: 132–42. doi:10.1111/j.1600-065X.2008.00644.x. PMC 2634846. PMID 18613833.
^Norman P (August 2014). "Selective JAK inhibitors in development for rheumatoid arthritis". Expert Opinion on Investigational Drugs. 23 (8): 1067–77. doi:10.1517/13543784.2014.918604. PMID 24818516. S2CID 21143324.
^"JAK Inhibitors Showing Promise for Many Skin Problems - Conditions ranging from alopecia to vitiligo". 6 July 2017. Archived from the original on 13 July 2017. Retrieved 9 July 2017.
^Forster M, Gehringer M, Laufer SA (September 2017). "Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting". Bioorganic & Medicinal Chemistry Letters. 27 (18): 4229–4237. doi:10.1016/j.bmcl.2017.07.079. PMID 28844493.
and 27 Related for: Janus kinase inhibitor information
A Januskinaseinhibitor, also known as JAK inhibitor or jakinib, is a type of immune modulating medication, which inhibits the activity of one or more...
Januskinase 3 inhibitors, also called JAK3 inhibitors, are a new class of immunomodulatory agents that inhibitJanuskinase 3. They are used for the treatment...
Januskinase 2 (commonly called JAK2) is a non-receptor tyrosine kinase. It is a member of the Januskinase family and has been implicated in signaling...
Januskinase (JAK) is a family of intracellular, non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. They...
levels. Ruxolitinib is a Januskinaseinhibitor (JAK inhibitor) with selectivity for subtypes JAK1 and JAK2. Ruxolitinib inhibits dysregulated JAK signaling...
unlike biologics. Examples: Tofacitinib Baricitinib JAK inhibitors act by inhibitingJanusKinases which consequently affect a cascade of enzymes responsible...
synthetic cyclohexylamino pyrrolopyrimidine januskinaseinhibitor that is relatively selective for JAK1. It inhibits signal transduction when the JAK is activated...
It is an inhibitor of Januskinases JAK1 and JAK2, acting as an ATP competitor with IC50 values of 11 and 18 nM, respectively. The inhibitor is significantly...
Tyrosine-protein kinase JAK3 is a tyrosine kinase enzyme that in humans is encoded by the JAK3 gene. Januskinase 3 is a tyrosine kinase that belongs to the janus family...
Deuruxolitinib (CTP-543) is a Januskinaseinhibitor selective for JAK1 and JAK2. It is in development to treat alopecia areata. If approved the drug would...
medication used for the treatment of atopic dermatitis (eczema). It is a Januskinaseinhibitor and it was developed by Pfizer. It is taken by mouth. The most common...
2002.04837.x. PMID 12410698. S2CID 42396825. Qi F, Liu F, Gao L. JanusKinaseInhibitors in the Treatment of Vitiligo: A Review. Front Immunol. 2021 Nov...
Crisaborole, an inhibitor of PDE-4, is also effective and safe as a topical treatment for mild-to-moderate AD. Ruxolitinib, a Januskinaseinhibitor, has uncertain...
rheumatoid arthritis. It belongs to the class of drugs known as Januskinaseinhibitors (JAK inhibitors). Peficitinib was approved for use in Japan in 2019. Kivitz...
juvenile idiopathic arthritis, and ulcerative colitis. It is a januskinase (JAK) inhibitor, discovered and developed by the National Institutes of Health...
rheumatoid arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of januskinase (JAK), blocking the subtypes JAK1 and JAK2. Baricitinib is approved...
Jaktinib is a januskinaseinhibitor under development for myelofibrosis. It is a deuterated-drug analog of momelotinib. Zhang, Yi; Zhou, Hu; Jiang, Zhongxing;...
treatment of mild to moderate atopic dermatitis. It is a topical Januskinaseinhibitor. Atopic dermatitis (AD) may be treated with narrowband UVB, which...
Eli Lilly for treatment of cancer. It is a small molecule JAK2 (Januskinase) inhibitor, with additional minor inhibition of STAT3. In phase I trial, 16%...
alopecia areata (hair loss). Ritlecitinib is a kinaseinhibitor which inhibitsJanuskinase 3 and tyrosine kinase. Ritlecitinib was approved for medical use...
of cancer. It is an inhibitor of the kinases fms-like tyrosine kinase 3 (FLT3), Januskinase 2 (JAK2), tropomyosin receptor kinase (trk) A (TrkA), TrkB...
may result in cancer. Hence kinaseinhibitors such as imatinib are frequently used to treat malignancies. Januskinases are another notable example of...
Ivarmacitinib (SHR0302) is a small molecule drug and selective januskinase 1 (JAK1) inhibitor. It is being developed for ulcerative colitis, eczema, alopecia...
and effective in animal models of other prurituses Oclacitinib, a januskinaseinhibitor used to control pruritus in dogs. Burow's solution, an astringent...
who are Januskinase (JAK) inhibitor naïve or have been treated with ruxolitinib. Fedratinib acts as a competitive inhibitor of protein kinase JAK-2 with...
Global Information